Following our previous studies,1 novel (arene)ruthenium(II) complexes containing neutral chelating nitrogen ligands, with general formula [Ru(arene)(L’)Cl]Cl, have been prepared by reacting the ligands L’ (L’ in general; in detail, L1 = bis(pyrazol-1-yl)methane; L2 = bis(3,5-dimethylpyrazol-1-yl) methane) with some dinuclear organometallic acceptors of ruthenium, such as (para-cymene)ruthenium(II) dichloride, (benzene)ruthenium(II) dichloride and (hexamethylbenzene)ruthenium(II) dichloride. The solid-state structures of these half-sandwich organometallic complexes were determined by X-ray crystallographic studies.1 Their antiproliferative properties were assessed in vitro and in vivo screening assays and it was found that the Ru(II) complexes exhibit potent antiproliferative activity against different human malignant cancer cells, even in comparison with cisplatin and NAMI-A (Figure 1). Moreover, our data clearly that some Ru(II) complexes are characterized by a strong ability to block cells migration associated with a low toxicity.
Antiproliferative Activity of a New (Arene)Ruthenium(II) Complex on a Model of Breast Cancer
MARCHETTI, Fabio;PETTINARI, Riccardo;PETTINARI, Claudio;MONTANI, Maura;AMICI, Augusto;LUPIDI, Giulio;MARCHINI, Cristina
2013-01-01
Abstract
Following our previous studies,1 novel (arene)ruthenium(II) complexes containing neutral chelating nitrogen ligands, with general formula [Ru(arene)(L’)Cl]Cl, have been prepared by reacting the ligands L’ (L’ in general; in detail, L1 = bis(pyrazol-1-yl)methane; L2 = bis(3,5-dimethylpyrazol-1-yl) methane) with some dinuclear organometallic acceptors of ruthenium, such as (para-cymene)ruthenium(II) dichloride, (benzene)ruthenium(II) dichloride and (hexamethylbenzene)ruthenium(II) dichloride. The solid-state structures of these half-sandwich organometallic complexes were determined by X-ray crystallographic studies.1 Their antiproliferative properties were assessed in vitro and in vivo screening assays and it was found that the Ru(II) complexes exhibit potent antiproliferative activity against different human malignant cancer cells, even in comparison with cisplatin and NAMI-A (Figure 1). Moreover, our data clearly that some Ru(II) complexes are characterized by a strong ability to block cells migration associated with a low toxicity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
